



HEALTHY HEART

VOLUME-13 | ISSUE-146 | JANUARY 05, 2022

Price : ₹ 5/-

Honorary Editor :

Dr. Vipul Kapoor

Interventional Cardiologist



Dear Friends,

Hope you and your family are healthy and safe during this pandemic.

This edition of Healthy Heart cover-up two very important topics namely Troponin levels and CAD Risk and Myocardial Injury after Non-Cardiac Surgery (MINS).

The common factor in both of the above situations is the use of Troponin measurement to prognosticate relatively stable and asymptomatic patients.

Hope you will find the discussion fruitful and useful in your routine clinical practice.

Feel free to interact if you have any questions or double.



Troponin Levels Tied to Increased CAD Risk, May Guide Imaging

Patients who have myocardial infarction (MI) ruled out in the emergency department but still have intermediate high-sensitivity cardiac troponin concentrations are three times more likely to have coronary artery disease (CAD) than patients who are ruled out with low troponin concentrations, a new study shows.

The finding suggests that high-sensitivity cardiac troponin could help select which patients need coronary computed tomography angiography (CCTA) to find occult CAD and guide the use of preventive therapy to prevent future MI, the authors say.

The study was published September 27 in the Journal of the American College of Cardiology.

The introduction of early rule-out pathways for myocardial infarction have increased the proportion of patients directly discharged from the Emergency Department.

Current guidelines are unclear how to further evaluate patients without myocardial infarction and there is little evidence to guide further testing in the high-sensitivity cardiac troponin era. As such, most clinicians select

patients for further testing and follow up based on whether their symptoms sound like angina or not.

PRECISE-CTCA (Troponin to Risk Stratify Patients with Acute Chest Pain for Computed Tomography Coronary Angiography) was a prospective cohort study that enrolled 250 patients from the emergency department in whom myocardial infarction was excluded.

Patients with intermediate (5 ng/L to the sex-specific 99th percentile threshold) and low (< 5 ng/L) high-sensitivity cardiac troponin concentrations were invited for an early outpatient CT coronary angiogram.

The mean age of the study participants was 61 ± 12 years, and 31% were women.

Overall, 42.4% of patients had angina symptoms, 12.8% had typical angina, and 29.6% had atypical angina. The remainder were classified as having nonanginal chest pain.

Patients with intermediate troponin concentrations were more than three times more likely to have CAD than those with low troponin concentrations (odds ratio, 3.33; 95% confidence interval, 1.92 - 5.78).

Cardiologists

Dr. Vipul Kapoor (M) +91-98240 99848	Dr. Urmil Shah (M) +91-98250 66939
Dr. Tejas V. Patel (M) +91-89403 05130	Dr. Hemang Baxi (M) +91-98250 30111
Dr. Hiren Kevadiya (M) +91-98254 65205	Dr. Anish Chandarana (M) +91-98250 96922
Dr. Gunvant Patel (M) +91-98240 61266	Dr. Ajay Naik (M) +91-98250 82666
Dr. Keyur Parikh (M) +91-98250 26999	Dr. Satya Gupta (M) +91-99250 45780
Dr. Milan Chag (M) +91-98240 22107	

Congenital & Structural Heart Disease Specialist

Dr. Kashyap Sheth (M) +91-99246 12288	Dr. Milan Chag (M) +91-98240 22107
Dr. Divyesh Sadadiwala (M) +91-8238339980	

Cardiothoracic & Vascular Surgeons

Dr. Dhiren Shah (M) +91-98255 75933
Dr. Dhaval Naik (M) +91-90991 11133
Dr. Amit Chandan (M) +91-96990 84097
Dr. Kishore Gupta (M) +91-99142 81008
Dr. Nikunj Vyas (M) +91-73531 65955

Paediatric & Structural Heart Surgeons

Dr. Shaunak Shah (M) +91-98250 44502

Cardiovascular, Thoracic & Thoracoscopic Surgeon

Dr. Pranav Modi (M) +91-99240 84700

Cardiac Anaesthetists

Dr. Niren Bhavsar (M) +91-98795 71917
Dr. Hiren Dholakia (M) +91-95863 75818
Dr. Chintan Sheth (M) +91-91732 04454

Cardiac Electrophysiologist

Dr. Ajay Naik (M) +91-98250 82666
Dr. Hiren Kevadiya (M) +91-98254 65205

Neonatologist and Paediatric Intensivist

Dr. Amit Chitaliya (M) +91-90999 87400
--



In contrast, the proportion of patients with typical or atypical angina who had CAD was the same as those who were considered to have nonanginal chest pain.

Most patients found to have CAD (53.2%, or 83 of 156 patients) did not have a previous diagnosis and were not on antiplatelet and statin therapies before they underwent CCTA.

Dr Nicholas L. Mills

"We know that patients with intermediate cardiac troponin concentrations are 10-fold more likely to have a cardiovascular event 1 year following the index hospital presentation than those with low cardiac troponins," senior author Nicholas L. Mills.

"The routine use of coronary computed tomographic angiography in those with intermediate troponin concentrations could help us identify patients with unrecognized coronary artery disease and target preventative therapy more effectively," Mills said.

These data can inform the selection of patients for CCTA, but further studies are needed to determine if this approach can improve outcomes, he said.

"We are currently evaluating whether troponin guided CTCA reduces the risk of future myocardial infarction or cardiac death compared to standard care in TARGET-CTCA, a large multicenter, randomized controlled trial funded by the British Heart Foundation."

Take Troponin Values into Account

Dr Kavitha Chinnaiyan

"Instead of focusing entirely on the 'rule-out' threshold of high-sensitivity troponin, perhaps the time has come to consider the actual troponin values in an individual patient to determine the need for additional testing with CTA [computed tomography angiography]," Kavitha Chinnaiyan, MD, and James L. Januzzi Jr, MD, write in an accompanying editorial.

"This study was a very interesting one,"

Chinnaiyan told theheart.org "Usually what happens is you come into the hospital, you get a high sensitivity troponin, if it is less than the cut off, then you're sent home; it's really not a heart attack so we don't need to worry about it. But that may not be the full story," she said.

"As these investigators show, even within the normal range, if your troponin is on the higher side, you have a higher burden of disease, your risk factors tend to be higher, and your risk for having an event is probably higher. They highlight the importance of looking at the actual value of the troponin rather than looking at it as being positive or negative," she added.

AHA Issues Scientific Statement on Myocardial Injury After Noncardiac Surgery

Accumulating evidence shows myocardial injuries are common after noncardiac surgery and prognostically important even with clinically silent troponin elevations.

To improve recognition and understanding, the American Heart Association (AHA) issued its first scientific statement reviewing the diagnostic criteria for myocardial injury after noncardiac surgery (MINS) and offering current best practices for surveillance, prevention, and management of this relatively new diagnosis, first introduced in 2014.

"That's only 7, 8 years ago and there was a lot of skepticism because the most important thing is that we are dealing with asymptomatic patients and if you have a troponin elevation, or any kind of lab elevation, most clinicians would say, 'why

should you care, the patient doesn't have any symptoms'," Kurt Ruetzler, MD, PhD, told theheart.org.

"But over the last few years we were providing a lot of evidence that, unfortunately, a troponin elevation, no matter if the patient is symptomatic or not, is important in terms of mortality for these patients. So now is the time for this [statement] because we have enough evidence to summarize this and make everyone aware," said Ruetzler, an anesthesiologist at the Cleveland Clinic.

Research suggests about 20% of noncardiac surgeries are complicated by MINS and about 90% of patients have no identifiable symptoms.

Diagnostic criteria include at least one elevated postoperative troponin T level

above the 99th percentile upper reference limit (URL) for the assay judged to be due to an ischemic mechanism (i.e., supply demand mismatch or athero-thrombosis), with or without ischemic symptoms or electrocardiographic abnormalities. When using fourth-generation and high-sensitivity troponin T (hs-TnT) assays, available "prognostically important" thresholds should be considered instead of the 99th percentile URL, the writing group notes.

Although the troponin elevations must occur in the first 30 days after surgery, data from the VISION trial show that 94.1% of MINS diagnoses occurred by the second day after surgery.

The diagnosis of MINS is more likely to occur in people with pre-existing cardiovascular



risk factors, including older age (especially 75 years and older), male sex, diabetes, hypertension, heart failure, obstructive sleep apnea, and anemia.

Studies also show that people undergoing emergency surgery have a two- to threefold higher adjusted odds of MINS, and that the risks for MINS are higher with several types of surgery, including vascular procedures (especially open aortic or infrainguinal surgery) and general abdominal surgery, the writing group notes

Importantly, evidence from prospective and retrospective analyses clearly indicate that troponin T elevations after noncardiac surgery are independently associated with short-and long-term mortality, Ruetzler said. In VISION, for example, the 30-day mortality rate was 3% with peak postsurgery hs-TnT levels of at least 20 ng/L to less than 65 ng/L and ballooned to 29.6% for patients with levels above 1000 ng/L.

"There are three important things," he said, "MINS is common, silent, and deadly."

Who to Screen

The writing group recommends troponin measurements before and in the first 48 to 72 hours after noncardiac surgery for patients at high clinical risk, such as adults 65 years and older or adults 45 years and older with established coronary or peripheral atherosclerotic cardiovascular disease.

If a postoperative troponin level is elevated but a recent previous measurement isn't available, a second test should be performed to determine whether a rising or falling pattern, indicative of acute myocardial injury, is present, they note.

"With this statement, we are providing the scientific background but the problem, of course, is there are a lot of resources needed

to actually implement it and financial things to consider," observed Ruetzler. "But we strongly believe it needs to be done."

Although some guidelines recommend systematic screening with perioperative cardiac troponin T for patients at risk for postoperative complications, there has been resistance to the broad application of this strategy because of the lack of guidance regarding which patients to screen, which criteria to use for the diagnosis of perioperative myocardial injury, and how to manage these patients, observes clinical cardiologist Danielle Menosi Gualandro, MD, PhD.

"This statement is a major step in the field of myocardial injury and hopefully the first step to promote the broad use of troponin screening in people at risk of cardiovascular complications," she says in a related commentary. "Increased screening can help to improve patient care and reduce cardiac complications and mortality of patients undergoing noncardiac surgery."

Although there's no consensus about the diagnostic thresholds for several cardiac troponin I assays, Gualandro notes that her team recently reported that MINS and acute perioperative myocardial injury diagnosed with hs-troponin I are independent predictors of mortality and major cardiovascular events at 30 days and 1 year.

Postop Management of MINS

The writing group notes a lack of prospective data regarding management of patients diagnosed with MINS, but the consensus is that treatment should be tailored to the etiology. When there is doubt about the mechanism, additional cardiovascular testing may be warranted.

The document provides a lot of retrospective evidence that intraoperative and postoperative blood pressure is very important in terms of avoidance of MINS, Ruetzler said, but the overall optimal treatment options are unclear.

The strongest evidence available thus far on postoperative anticoagulation in MINS comes from the placebo-controlled MANAGE trial, in which daily dabigatran (Pradaxa, Boehringer Ingelheim) showed a 28% reduction in the risk for major vascular events over 16 months without increasing major bleeding.

"So-called secondary prophylaxis is extremely important for these patients, so it makes sense to borrow the evidence from patients with a myocardial infarction in the nonsurgical setting," Ruetzler said. "And there's a lot of evidence for aspirin but also for statins, smoking cessation, lifestyle changes, and weight loss, so I think all of this should be done in these patients."


Future trials will provide new insights into MINS, including the GUARDIAN trial, which is testing whether tight perioperative blood pressure management reduces serious perfusion-related complications after major noncardiac surgery and the recently completed but not yet reported POISE-3 trial, he said. The latter examined the effects of tranexamic acid versus placebo and managing hypotension versus standard of care on a composite cardiovascular endpoint at 1 year in patients at risk for a perioperative cardiovascular event undergoing noncardiac surgery.



Perfect Team Work Saves Life

Case write up - Dr Amit Chitaliya

Feeling happy and humbled to share the journey of a newly born with one of the most complex disease -tracheo esophageal fistula-a lethal congenital disorder.



One fine day, Department of Paediatric Critical care services in CIMS Hospital- receives a call to urgently attend Caesarean

section as mother was also suffering from congenital heart disease Large VSD With severe PAH and expected newborn is going to be depressed at birth as per history shared by our colleague Dr Devang Patel-High risk delivery & Fatal medicine specialist, who performed this high risk emergency LSCS.As expected in OR-There was a tense atmosphere indeed while I Reached along with my team.Soon mom needed ventilator support (ELECTIVELY FOR LSCS Under GA) and our heart beats were up.Our worry escalated as baby delivered had Meconium Aspiration with no spontaneous breaths →our team was on toes to bring the breathing back and do CPR effectively saving baby and his lungs specially when we found that child had very narrow glottis and subglotic opening to intubate !! With all efforts and successful intubation →at 90 seconds of CPR baby showed a good effort of breathing.Here came an another surprise ???! This cute little baby soon found to be having rare congenital anomalies which if not dealt well are not compatible with life!! Tracheo oesophageal Fistula and large Heart defects as well (ASD+VSD). Team who fought to bring the life back in OR was now again worried for the baby as it's a major surgery to undergo for neonate where god made defects had to be rectified and detached food pipe ends need to be re joined and abnormal attachment from wind pipe and food pipe has to be separated .Team of paediatric Surgeon+Neonatologist+Paediatric Cardio all geared up for tough per op & post op care.Till child's MAS - meconium aspiration got better and PAH and LV dysfunction improved we supported the baby in NICU For around 48 odd hours.Care of Pulmonary hypertension with MAS And tracheoesophageal fistula is very difficult and morbidity is usually anticipated in such cases.Team worked hard and on later

took up for surgery which went really very well with excellent team work provided.Child had leak free post op days and we could extubate the child after 3 days post op stabilisation on ventilator . We preferred early TPN being complex GI surgery in newborn which helps keeping child without negative nitrogen balance .Eventually child had an intact survival and when this is being written, he is at home 21 days post discharge in his mumma's lap (yes,.. she also survived with all odds and due to excellent support of adult ICU Team and High risk delivery Team).Stay in Hospital for baby was just 12 days.


This is a perfect example of ideal Perinatal unit and advantage of in-utero transfer of sick baby.Worth to note how presence of All super specialist under 1 roof for mom and baby makes a huge difference in survival of both - Jaccha and bachcha !

We sincerely thank Dr Kunal sheth for very effective n leak free surgery .(consultant Paediatric Surgeon), Dr Devang & OB GY team for right time emergent LSCS. Our competent and experienced NICU/PICU team is feeling happy continuing it's 11 year long journey of such satisfactory outcomes. We hope in INDIA - value of institutional delivery increase by seeing such a great example of intact survival of mom and baby both despite all odds.

Dr. Amit Chitaliya - MB, D.Ped,
Paediatric Critical Care (Berlin),
Neonatologist and Pediatric Intensivist,
Director - Paediatric Critical Care



PROTECT YOUR LOVED ONES FROM COVID-19



**COVID Vaccine Drive for
Kids and Elders at**

**CIMS Super
Specialty Hospital**

BOOK YOUR SLOT TODAY

Call +91 90990 67988

Get your Child and Elders Vaccinated

***Eligibility Criteria :**

- Citizens (Age 60 Yrs+ Co-morbid)
- A gap of 39 weeks between 2nd Dose and Booster Shots

*Timings & other norms will be followed as per the guidelines.

DO NOT IGNORE THESE SYMPTOMS

GET CARE FAST


In case of following symptoms please rush to your nearby hospital

HEART ATTACK SYMPTOMS

- Chest pain or pressure
- Tightness, burning or heaviness in the chest
- Shortness of breath
- Profuse sweating
- Nausea and vomiting




24 X 7 MEDICAL HELPLINE +91-70 69 00 00 00



Class I Indication for Cardiac Transplantation

- Cardiogenic shock requiring mechanical assistance
- Refractory heart failure with continuous inotropic infusion
- NYHA functional class 3 and 4 with a poor 12 months prognosis
- Progressive symptoms with maximal therapy
- Severe symptomatic hypertrophic or restrictive cardiomyopathy
- Medical refractory angina with unsuitable anatomy for revascularization
- Life threatening ventricular arrhythmias despite aggressive medical and device interventions
- Cardiac tumors with low likelihood of metastasis
- Hypoplastic left heart and complex congenital heart disease

Contraindication

- 
- Age > 65 years
 - Fixed pulmonary vascular resistance > 6 wood units
 - Brittle Diabetes with end organ damage
 - Active infection
 - Major debilitating co-morbid disease
 - Active or recent malignancy (<2 years)
 - HIV seroconversion
 - Morbid obesity (BMI > 35)
 - History of severe mental illness or psychological instability
 - Evidence of tobacco, alcohol or drug abuse

CIMS SUPER SPECIALITY HOSPITAL

CIMS CANCER CENTRE

We **Were** - We **Are** - We **Will Be**
FIGHTING For You
With You



Dedicated Cancer Centre



State-of-the-art Linear Accelerators



Integrated Cancer OPD



State-of-the-art Operation Theatres

ONCOLOGY CLINICS

Breast Oncology ■ Head-Neck Oncology ■ Uro-Oncology ■ Gynaec Oncology ■ Cardio Oncology
Neuro Oncology ■ Gastro Oncology ■ Thoracic Oncology ■ Ortho Oncology

STATE-OF-THE-ART RADIOLOGY & HISTOPATHOLOGY DEPARTMENT

SPECIAL SERVICES

Cancer Supportive Care Unit ■ Cancer Screening Programmes
Cancer Rehabilitation Unit (Speech & Swallowing, Physiotherapy) ■ Recreational Activity

FOR APPOINTMENT CALL +91-79-4805 1257 | MOBILE : +91-99792 75555
TIME : 9:00 AM - 7:00 PM (MON TO SAT) | EMAIL : cims.cancer@cimshospital.org



RADIATION ONCOLOGY

DR. MAULIK BHENSDADIA
DR. MALHAR PATEL
DR. PRAPTI PATEL DESAI
DR. HIRAK VYAS
DR. DEVANG BHAVSAR



SURGICAL ONCOLOGY

DR. ASHOK PATEL
DR. DARSHAN BHANSALI
DR. JAYESH PATEL
DR. NATOO PATEL
DR. TARANG PATEL
DR. MAHAVIR TADIYA
DR. MONA SHAH

SURGICAL ONCOLOGY ASSOCIATES

DR. MANISH GANDHI
DR. VATSAL KOTHARI
DR. REEDHAM MEHTA
DR. RUPESH SHAH



MEDICAL ONCOLOGY

DR. CHIRAG DESAI
DR. RAHUL JAISWAL
DR. CHINTAN SHAH
DR. SANKET SHAH
DR. DEEPA TRIVEDI
DR. KSHITIJ DOMADIA

DR. UDAY PATEL
(Interventional Radiologist)
DR. GAUTAM SHAH
(Histopathologist)



Healthy Heart Registered under **RNI No. GUJENG/2008/28043**

Published on 5th of every month

Permitted to post at PSO, Ahmedabad-380002 on the 12th to 17th of every month under

Postal Registration No. **GAMC-1725/2021-23** issued by SSP Ahmedabad valid upto 31st December, 2023

Licence to Post Without Prepayment No. **PMG/NG/055/2021-23** valid upto 31st December, 2023


If undelivered Please Return to :

CIMS Hospital, Nr. Shukan Mall,
Off Science City Road, Sola, Ahmedabad-380060.
Ph. : +91-79-2771 2771-72
Fax: +91-79-2771 2770
Mobile : +91-98250 66664, 98250 66668

Subscribe "Healthy Heart" : Get your "Healthy Heart", the information of the latest medical updates only ₹ 60/- for one year.
To subscribe pay ₹ 60/- in cash or cheque/DD at CIMS Hospital Pvt. Ltd. Nr. Shukan Mall, Off Science City Road, Sola, Ahmedabad-380060. Phone : +91-79-4805 2823. Cheque/DD should be in the name of : **"CIMS Hospital Pvt. Ltd."**
Please provide your **complete postal address with pincode, phone, mobile and email id** along with your subscription

CIMS SUPER SPECIALITY HOSPITAL-AHMEDABAD

Gujarat's First Heart Transplant Centre



26TH HEART TRANSPLANT

January 05, 2022

Saving Lives and Livelihoods

CIMS Hospital : Regd Office: Plot No.67/1, Opp. Panchamrut Bungalows, Nr. Shukan Mall, Off Science City Road, Sola, Ahmedabad - 380060.

Ph. : +91-79-2771 2771-72 | 4805 1111

CIMS Hospital Pvt. Ltd. | CIN : U85110GJ2001PTC039962 | info@cims.org | www.cims.org

Printed, Published and Edited by Dr. Keyur Parikh on behalf of the CIMS Hospital

Printed at Hari Om Printery, 15/1, Nagori Estate, Opp. E.S.I. Dispensary, Dudheshwar Road, Ahmedabad-380004.

Published from CIMS Hospital, Nr. Shukan Mall, Off Science City Road, Sola, Ahmedabad-380060.